Brenner Annette K, Aasebø Elise, Hernandez-Valladares Maria, Selheim Frode, Berven Frode, Grønningsæter Ida-Sofie, Bartaula-Brevik Sushma, Bruserud Øystein
Department of Medicine, Haukeland University Hospital; 5021 Bergen, Norwa.
Section for Hematology, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.
Cancers (Basel). 2019 Jan 10;11(1):73. doi: 10.3390/cancers11010073.
Acute myeloid leukemia (AML) is an aggressive malignancy, which is highly heterogeneous with regard to chemosensitivity and biological features. The AML cell population is organized in a hierarchy that is reflected in the in vitro growth characteristics, with only a minority of cells being able to proliferate for more than two weeks. In this study, we investigated the ability of AML stem cells to survive and proliferate in suspension cultures in the presence of exogenous mediators but without supporting non-leukemic cells. We saw that a high number of maintained stem cells (i.e., a large number of clonogenic cells after five weeks of culture) was associated with decreased overall survival for patients receiving intensive chemotherapy; this prognostic impact was also detected in the multivariate/adjusted analysis. Furthermore, the patients with many clonogenic cells presented more frequently with mutations in transcription-related genes, and also showed a higher abundance of proteins involved in transcription at the time of diagnosis. In conclusion, the growth characteristics of the long-term proliferating leukemic stem cells seem to have an independent prognostic impact in human AML, and these characteristics appear to be reflected by the mutational landscape and the proteome of the patients at the time of diagnosis.
急性髓系白血病(AML)是一种侵袭性恶性肿瘤,在化疗敏感性和生物学特征方面具有高度异质性。AML细胞群体呈层级结构组织,这在体外生长特性中有所体现,只有少数细胞能够增殖超过两周。在本研究中,我们调查了AML干细胞在外源介质存在但无非白血病细胞支持的悬浮培养中存活和增殖的能力。我们发现,大量维持的干细胞(即培养五周后大量克隆形成细胞)与接受强化化疗患者的总生存期缩短相关;在多变量/校正分析中也检测到了这种预后影响。此外,具有许多克隆形成细胞的患者更频繁地出现转录相关基因突变,并且在诊断时还显示出参与转录的蛋白质丰度更高。总之,长期增殖的白血病干细胞的生长特性似乎对人类AML具有独立的预后影响,并且这些特征似乎在诊断时由患者的突变图谱和蛋白质组所反映。